Alex Zhavoronkov (Insilico)
July 15, 2020 05:27 AM EDTUpdated 06:15 AM
Financing
R&D

'Longevi­ty as a ser­vice': In­sil­i­co spins off AI biotech that trains deep learn­ing on an­ti-ag­ing treat­ments

Max Gelman

Senior Editor

Since its in­cep­tion in 2014, In­sil­i­co has racked up deal af­ter deal on the promise that ar­ti­fi­cial in­tel­li­gence can has­ten drug de­vel­op­ment, tout­ing …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

Trump an­nounces picks for FDA, CDC; No­var­tis seeks bolt-on deals, rais­es guid­ance; RFK Jr., Elon Musk may find ...

For CDC, Trump picks Dave Wel­don, a for­mer con­gress­man who pushed for vac­cine in­jury claims

Trump names Johns Hop­kins re­searcher Mar­ty Makary to lead the FDA; al­so names CDC, Sur­geon Gen­er­al picks

FDA ap­proves Bridge­Bio's heart dis­ease drug, set­ting up com­pe­ti­tion with Pfiz­er, Al­ny­lam

Sanofi in­tro­duces new 340B pay­ment mod­el — re­port

sponsored

Are pro­grams with com­pound­ed GLP-1s safe for your pop­u­la­tion?

A service from the Financial Times